HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): L. Henry Edmunds, Jr Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gikakis, N. Articles by Edmunds, L. H. Search for Related Content PubMed PubMed Citation Articles by Gikakis, N. Articles by Edmunds, L. H., Jr

J Thorac Cardiovasc Surg 1998;116:1043-1051
© 1998 Mosby, Inc.

CARDIOPULMONARY SUPPORT AND PHYSIOLOGY

ENOXAPARIN SUPPRESSES THROMBIN FORMATION AND ACTIVITY DURING CARDIOPULMONARY BYPASS IN BABOONS

Supported by HL47186 from the National Heart Lung Blood Institute, National Institutes of Health, Bethesda, Md.

Received for publication Feb 12, 1998. Revisions requested April 15, 1998; revisions received July 14, 1998. Accepted for publication July 21, 1998. Address for reprints: L. Henry Edmunds, Jr, MD, Department of Surgery, Hospital of the University of Pennsylvania, Six Silverstein, 3400 Spruce St, Philadelphia, PA 19104.

Objective:This study tests the hypotheses that enoxaparin, a low molecular weight heparin and potent inhibitor of factor Xa, alone or in combination with standard heparin, inhibits thrombin formation and activity and modulates complement activation and neutrophil elastase release during cardiopulmonary bypass in baboons.
Methods: After preliminary studies to determine doses and possible species differences to anticoagulants and protamine, 27 anesthesized baboons had normothermic cardiopulmonary bypass with standard, unfractionated, porcine intestinal heparin, enoxaparin, or a combination of heparin and enoxaparin. Protamine in appropriate doses was used to reverse anticoagulation. Blood samples were obtained at 6 time points. Activated clotting times were monitored; template bleeding times were measured before and up to 24 hours after cardiopulmonary bypass.
Results: Hemodynamic measurements were not affected by the anticoagulant. Activated clotting times remained above 400 seconds throughout bypass, and no clots were observed. The anticoagulant did not alter platelet count, aggregation to adenosine diphosphate, release of ß-thromboglobulin, release of neutrophil elastase, or complement C3b/c and C4b/c. Enoxaparin alone, but not in combination, significantly reduced plasma levels of prothrombin fragment F1.2, fibrinopeptide A, and thrombin-antithrombin complexes but prolonged template bleeding times for more than 24 hours.
Conclusion: Enoxaparin significantly reduces thrombin formation and activity during cardiopulmonary bypass but does not suppress complement activation and neutrophil elastase release and is not adequately reversed by protamine after bypass.

This article has been cited by other articles:

				R. C. Becker Emerging constructs to maintain safety among patients with acute coronary syndromes requiring surgical coronary revascularization Eur. Heart J. Suppl., May 1, 2008; 10(suppl_D): D12 - D22. [Abstract] [Full Text] [PDF]

				J. W. Hammon Extracorporeal Circulation: The Response of Humoral and Cellular Elements of Blood to Extracorporeal Circulation Card. Surg. Adult, January 1, 2008; 3(2008): 370 - 389. [Full Text]

				A. Gruber, U. M. Marzec, L. Bush, E. Di Cera, J. A. Fernandez, M. A. Berny, E. I. Tucker, O. J. T. McCarty, J. H. Griffin, and S. R. Hanson Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates Blood, April 1, 2007; 109(9): 3733 - 3740. [Abstract] [Full Text] [PDF]

				L. H. Edmunds Jr. and R. W. Colman Extracorporeal Circulation: Thrombosis and Bleeding Card. Surg. Adult, January 1, 2003; 2(2003): 338 - 348. [Full Text]

				V. Mary, F. Wahl, A. Uzan, and J.-M. Stutzmann Enoxaparin in Experimental Stroke : Neuroprotection and Therapeutic Window of Opportunity Stroke, April 1, 2001; 32(4): 993 - 999. [Abstract] [Full Text] [PDF]

				R. S. Kiesz, P. Buszman, J. L. Martin, E. Deutsch, M. M. Rozek, E. Gaszewska, M. Rewicki, P. Seweryniak, M. Kosmider, and M. Tendera Local Delivery of Enoxaparin to Decrease Restenosis After Stenting: Results of Initial Multicenter Trial : Polish-American Local Lovenox NIR Assessment Study (The POLONIA Study) Circulation, January 2, 2001; 103(1): 26 - 31. [Abstract] [Full Text] [PDF]

				E. Prifti, M. Bonacchi, M. Leacche, and F. Miraldi Undergoing cardiopulmonary bypass using enoxaparin only during a cardiac transplantation procedure Eur. J. Cardiothorac. Surg., June 1, 2000; 17(6): 760 - 762. [Abstract] [Full Text] [PDF]